GenSight Biologics
GenSight Biologics is a Paris-based clinical-stage biopharmaceutical company developing AAV gene therapies for rare retinal neurodegenerative diseases, including LUMEVOQ for Leber Hereditary Optic Neuropathy and GS030 optogenetic therapy for Retinitis Pigmentosa, generating early revenue through Named Patient Access Programs in France, Israel, and the US.
- Company typePublic
- Founded2013
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
GenSight Biologics firmographics
Firmographics- Name
- GenSight Biologics
- Legal name
- GENSIGHT BIOLOGICS S.A.
- Website
- https://gensight-biologics.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GenSight Biologics is a Paris-based clinical-stage biopharmaceutical company developing AAV gene therapies for rare retinal neurodegenerative diseases, including LUMEVOQ for Leber Hereditary Optic Neuropathy and GS030 optogenetic therapy for Retinitis Pigmentosa, generating early revenue through Named Patient Access Programs in France, Israel, and the US.
- Ownership category
- akta.pro rank
GenSight Biologics industry classification
Industry- Product category
- Gene Therapy Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Ophthalmology Gene Therapies (HLAAACAG)
- akta.pro secondary industries
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Rare Ophthalmology Disorder Therapies (HLAIAIAK), AAV Vector Gene Therapy Developers (HLAAACAA), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
Keywords
Where GenSight Biologics is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
GenSight Biologics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Early Access Program Revenue: Revenue generated from Named Patient Early Access Programs (AAC) in France, Israel, and the United States. The company recorded €2.6 million in proceeds from early access treatments in March 2026, with additional treatments scheduled. These programs provide access to GS010/LUMEVOQ for ND4-LHON patients who would otherwise have no appropriate treatment option before full market authorization.
- Future Product Sales: Once market authorization is obtained, the company plans to commercialize its gene therapy products. LUMEVOQ MAA was filed in September 2020 and is currently under review. EMA decision was expected in Q2 2022 but has been delayed. The company is preparing for regulatory authorizations across multiple markets.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
GenSight Biologics product offering
Product offeringCore offering
GenSight Biologics is a clinical-stage biopharmaceutical company developing gene therapy-based treatments for retinal degenerative diseases and central nervous system disorders. Its lead product candidate GS010 (lenadogene nolparvovec / LUMEVOQ) is an AAV-based gene therapy delivered via intravitreal injection for Leber Hereditary Optic Neuropathy (LHON). The pipeline also includes GS030, an optogenetic therapy combining AAV-mediated gene therapy with proprietary light-stimulating goggles (GS030-MD) for Retinitis Pigmentosa.
Product overview
GenSight Biologics is a clinical-stage biopharma company developing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company leverages two core technology platforms: Mitochondrial Targeting Sequence (MTS) for mitochondrial gene therapy and optogenetics for vision restoration. The product portfolio consists of GS010 (lenadogene nolparvovec), an MTS-based gene therapy for Leber Hereditary Optic Neuropathy (LHON) currently completing clinical development and receiving early access authorizations in France, Israel, and the US; and GS030, an optogenetics therapy combining AAV-mediated gene therapy with wearable light-stimulating goggles (GS030-MD) for Retinitis Pigmentosa in Phase I/II PIONEER trial.
Differentiator
Problem solved
Functional benefit
Brands
- GS010: Gene therapy product candidate for Leber Hereditary Optic Neuropathy (LHON), also known as LUMEVOQ.
- GS030
Products and services
- GS010 (lenadogene nolparvovec / LUMEVOQ) Recombinant AAV serotype 2 (rAAV2/2) containing the wild-type mitochondrial ND4 gene (GS010) intended for single intravitreal injection treatment of ND4-LHON, the most severe mitochondrial mutation (G11778A) causing irreversible blindness in teens and young adults. Currently completing clinical development and receiving early access authorizations in France, Israel, and the United States.
- GS030 Optogenetic gene therapy product candidate combining an optimized AAV vector (GS030-DP) that expresses the light-sensitive opsin ChrimsonR in retinal ganglion cells, paired with proprietary light-stimulating goggles (GS030-MD). Designed to restore vision in patients with end-stage Retinitis Pigmentosa regardless of underlying genetic mutation.
- GS030-MD (Medical Device) Proprietary wearable light-stimulating goggles used in combination with GS030 gene therapy to project appropriate wavelength and intensity of light onto treated retinal ganglion cells for optogenetic vision restoration in Retinitis Pigmentosa patients.
Quantifiable outcome
- Phase III REFLECT trial demonstrated efficacy including better efficacy with bilateral treatment vs unilateral treatment for LHON
- +2 more outcomes
Companies that use GenSight Biologics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles1 record
GenSight Biologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
GenSight Biologics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- 15-20 National Hospital (Paris)corePrimary clinical partner in France for GS010/LUMEVOQ treatments and clinical studies. The hospital is the only institution in Europe conducting GS010 clinical studies and is the site for the French Named Patient Early Access Program. First patient treatments administered March 19, 2026.
- CatalentcoreManufacturing partner for technology transfer of GS010/LUMEVOQ production. Technology transfer to Catalent is underway for future clinical and commercial supply chain needs.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
GenSight Biologics competitors and assessment
Company assessmentEmerging players
- Coave Therapeutics: French clinical-stage gene therapy company developing AAV-based therapies for ocular and CNS diseases, including retinitis pigmentosa programs. Comparable as a European emerging player in the same gene therapy + ophthalmology space.
- Editas Medicine: Clinical-stage genome editing company (CRISPR/Cas9) with ophthalmology as a core area, including EDIT-101 for LCA10. Comparable as a clinical-stage genomic medicine developer in retinal disease using a related but distinct gene-modifying approach.
- Beacon Therapeutics: Clinical-stage ophthalmic gene therapy company with programs for X-linked retinitis pigmentosa and achromatopsia. Comparable emerging player building an AAV-based ophthalmology pipeline similar in scope to GenSight.
- SparingVision: French clinical-stage biotech developing gene therapies for retinitis pigmentosa, including mutation-independent approaches similar to GenSight's optogenetics platform. Comparable as a Paris-based emerging ophthalmology gene therapy company.
Broad incumbents
- Roche: Global pharmaceutical incumbent with a deep ophthalmology franchise (Lucentis, Vabysmo) and ownership of Spark Therapeutics. Indirect strategic comparable and potential acquirer of assets like GenSight's ocular gene therapy pipeline.
Direct peers
- Adverum Biotechnologies: Clinical-stage biotech developing gene therapies for ocular diseases (wet AMD, diabetic macular edema) using AAV vectors. Direct competitor in the ophthalmic AAV gene therapy space with similar intravitreal delivery approach.
- Spark Therapeutics: Developer of AAV-based gene therapies including Luxturna for inherited retinal dystrophy; the most direct comparable in ophthalmic AAV gene therapy. Acquired by Roche in 2019, providing a clear precedent for the strategic value of a clinically validated ocular gene therapy platform.
- MeiraGTx: Clinical-stage gene therapy company with multiple ocular programs (AAV for X-linked retinitis pigmentosa, achromatopsia) plus CNS and salivary gland programs. Comparable to GenSight as a clinical-stage AAV gene therapy developer with ophthalmology as a core focus.
- Nightstar Therapeutics: Clinical-stage gene therapy company focused on inherited retinal diseases (choroideremia, X-linked retinitis pigmentosa, achromatopsia) using AAV vectors. Acquired by Biogen for $800M, exemplifying the M&A appetite for ophthalmology gene therapy assets similar to GenSight's pipeline.
- REGENXBIO: Developer of AAV gene therapy platforms (NAV Technology) with ophthalmology programs including ABBV-RGX-314 for wet AMD/diabetic retinopathy. Provides both platform and product-level comparability for GenSight's AAV-based approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
GenSight Biologics social profiles
Digital presenceGenSight Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
GenSight Biologics leadership team
Management profileNumber of profiles
Profiles9 records
GenSight Biologics funding detail
Funding detailFunding overview
Funding rounds22 records
Investors20 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GenSight Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GenSight Biologics
What does GenSight Biologics do?
GenSight Biologics is a clinical-stage biopharmaceutical company developing gene therapy-based treatments for retinal degenerative diseases and central nervous system disorders. Its lead product candidate GS010 (lenadogene nolparvovec / LUMEVOQ) is an AAV-based gene therapy delivered via intravitreal injection for Leber Hereditary Optic Neuropathy (LHON). The pipeline also includes GS030, an optogenetic therapy combining AAV-mediated gene therapy with proprietary light-stimulating goggles (GS030-MD) for Retinitis Pigmentosa.
Is GenSight Biologics a public or private company?
GenSight Biologics is a public company. It is classified as public and is currently operating.
When was GenSight Biologics founded?
GenSight Biologics was founded in 2013. It employs 11 to 50 people.
Where is GenSight Biologics based?
GenSight Biologics is headquartered in Paris, France, in the Europe region.
How does GenSight Biologics make money?
Two revenue lines are on record. Early Access Program Revenue is the primary driver. The others are future Product Sales.
Who are GenSight Biologics's main competitors?
Emerging players on record are Coave Therapeutics, Editas Medicine, Beacon Therapeutics and SparingVision. Roche is listed as a broad incumbent. Direct peers are Adverum Biotechnologies, Spark Therapeutics, MeiraGTx, Nightstar Therapeutics and REGENXBIO.
Does GenSight Biologics have an API?
No public API is recorded for GenSight Biologics.
What industry is GenSight Biologics in?
GenSight Biologics's product category is Gene Therapy Pharmaceuticals. Its primary akta.pro industry code is HLAAACAG, Ophthalmology Gene Therapies, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 325414 and its SIC code is 2836.